Saudi Journal of Gastroenterology
Home About us Instructions Submission Subscribe Advertise Contact Login    Print this page  Email this page Small font sizeDefault font sizeIncrease font size 
Users Online: 674 
ORIGINAL ARTICLE
Year : 2011  |  Volume : 17  |  Issue : 2  |  Page : 114-118

Effect of interferon treatment on hearing of patients with chronic Hepatitis C


1 Department of ENT, College of Medicine, King Saud University, Riyadh, Saudi Arabia
2 Department of Medicine, Division of Gastroenterology & Hepatology, Riyadh Military Hospital, Riyadh, Saudi Arabia
3 Gastroenterology Division, Department of Medicine, King Saud University, Riyadh, Saudi Arabia

Correspondence Address:
Ahmed Al-Arfaj
Department of Otolaryngology, College of Medicine, King Saud University, P .O. Box 245, Riyadh 11411
Saudi Arabia
Login to access the Email id

Source of Support: College of Medicine Research Center (CMRC), King Saud University in Riyadh, Saudi Arabia (Grant No.06-553), Conflict of Interest: None


DOI: 10.4103/1319-3767.77240

Rights and Permissions

Background/Aim: Some reports in the literature have linked interferon therapy for the treatment of hepatitis C (HCV) with hearing loss. The aim of this study has been to examine the effects of interferon therapy on hearing of patients treated for HCV. Patients and Methods: Patients were recruited according to preset inclusion criteria from two centers. All patients received standard dose pegylated interferon (PEG-IFN a-2b or a-2a) plus ribavirin (RBV). All patients had pure-tone audiometry (PTA), tympanogram and distortion-product otoacoustic emission (DPOAE) before treatment, three months after initiation of treatment, and three months after completion of treatment. Results: Twenty one patients were prospectively recruited. The mean age was 45.7 years. The male to female ratio was 1.1:1. The mean PTA was 15.9 ± 5.3 before treatment, 17.4 ± 6.1 during treatment and 16.5 ± 5.1 after treatment. The differences between pre and mid, pre and post, as well as mid and post were not significantly different (P>0.05) in all audiological assessments. Conclusions: Our results indicate that PEG-IFN\RBV therapy does not have any impact on the hearing thresholds of patients with HCV.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed3233    
    Printed164    
    Emailed0    
    PDF Downloaded457    
    Comments [Add]    
    Cited by others 3    

Recommend this journal